Overview

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Status:
Unknown status

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type

Phase:

Phase 2

Details

Lead Sponsor:

SciClone Pharmaceuticals

Treatments:

Carboplatin
Cisplatin
Pemetrexed
Thymalfasin